Send to:

Choose Destination
See comment in PubMed Commons below
Cancer Treat Rep. 1987 Jun;71(6):643-4.

Lack of benefit of adjunctive chemotherapy in stage I malignant melanoma: a Southwest Oncology Group Study.


In 1975, the Southwest Oncology Group initiated an adjuvant study in localized malignant melanoma testing the value of aggressive chemotherapy using carmustine, hydroxyurea, and dacarbazine versus a control arm. Median disease-free survival was 7.1 years for the control arm and 6 years for the treatment arm. Survival was identical for both arms with 65% of the patients alive at 6 years. We conclude that carmustine, hydroxyurea, and dacarbazine chemotherapy is of no value as adjuvant treatment for localized melanoma.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk